KPTI Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Myelofibrosis Clinical And Regulatory ProgressThe SENTRY results and constructive FDA feedback support a potential accelerated approval for selinexor plus ruxolitinib. If confirmed, this could expand XPOVIO into a sizable myelofibrosis market and materially improve the company’s long-term growth profile.
Established Commercial PlatformXPOVIO provides an existing revenue base, commercial infrastructure, patient support capabilities, and market access experience. Stable product sales and reaffirmed guidance give Karyopharm a platform from which to launch additional indications if regulatory milestones are achieved.
High Gross Margin And Cost PrioritizationThe product economics are attractive, while lower R&D and SG&A spending indicates prioritization of higher-value programs. Sustaining this discipline could improve operating leverage as revenue expands, although the company still needs substantially greater scale to reach profitability.
Bears Say
Stressed Balance Sheet And Financing DependenceNegative equity and debt that is large relative to the asset base materially restrict financial flexibility. The capital structure leaves Karyopharm dependent on new financing, waivers, or strategic transactions, increasing dilution, refinancing, and potential default risk.
Persistent Losses And Negative Cash FlowKaryopharm remains far from self-funding because operating expenses materially exceed its revenue base. Continued cash consumption limits the company’s ability to independently finance clinical development and commercialization, making execution increasingly dependent on external capital.
Pipeline Concentration And Confirmatory Approval RiskThe endometrial cancer failure reduces diversification and increases reliance on the myelofibrosis program. Even with accelerated approval, confirmatory overall-survival data will mature over years, leaving label conversion, timing, and commercial expectations exposed to clinical and regulatory uncertainty.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is CHF35.76M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF1.882 earnings per share for the quarter, missing the consensus estimate of -CHF1.113 by -CHF0.769.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Karyopharm Therapeutics have?
Currently, no data Available
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -CHF1.882 in its last earnings report, missing expectations of -CHF1.113. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in CH:KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.81 (― Upside)
CHF5.81 (― Upside)
Blogger Sentiment
Bullish
CH:KPTI Sentiment 66%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.14%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.View all CH:KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
―Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―